<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Genzyme&#8217;s Second Try for Bioenvision Will Also Fail, Sources Predict; Institutional Investors Seek Higher Price</title>
	<atom:link href="http://www.xconomy.com/boston/2007/07/09/genzymes-second-try-for-bioenvision-will-fail-again-sources-predict-institutional-investors-seek-higher-price/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.xconomy.com/boston/2007/07/09/genzymes-second-try-for-bioenvision-will-fail-again-sources-predict-institutional-investors-seek-higher-price/</link>
	<description>Business + Technology in the Exponential Economy</description>
	<lastBuildDate>Sun, 22 Nov 2009 18:21:13 -0600</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.6</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: Robert Buderi</title>
		<link>http://www.xconomy.com/boston/2007/07/09/genzymes-second-try-for-bioenvision-will-fail-again-sources-predict-institutional-investors-seek-higher-price/comment-page-1/#comment-569</link>
		<dc:creator>Robert Buderi</dc:creator>
		<pubDate>Wed, 22 Aug 2007 20:19:54 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/2007/07/09/genzymes-second-try-for-bioenvision-will-fail-again-sources-predict-institutional-investors-seek-higher-price/#comment-569</guid>
		<description>Tom,

I don&#039;t know the answer to this, but it&#039;s a great question and I can well imagine the difficulty in finding a clear answer. We&#039;ll see if we can learn anything, and please let us know if you come across anything as well.</description>
		<content:encoded><![CDATA[<p>Tom,</p>
<p>I don&#8217;t know the answer to this, but it&#8217;s a great question and I can well imagine the difficulty in finding a clear answer. We&#8217;ll see if we can learn anything, and please let us know if you come across anything as well.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Tom Kilbourne</title>
		<link>http://www.xconomy.com/boston/2007/07/09/genzymes-second-try-for-bioenvision-will-fail-again-sources-predict-institutional-investors-seek-higher-price/comment-page-1/#comment-568</link>
		<dc:creator>Tom Kilbourne</dc:creator>
		<pubDate>Wed, 22 Aug 2007 19:40:21 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/2007/07/09/genzymes-second-try-for-bioenvision-will-fail-again-sources-predict-institutional-investors-seek-higher-price/#comment-568</guid>
		<description>Is there any recourse for those of us who signed the agreement selling our BIVN shares to Genzyme thinking that it was a done deal (as explained to me by E-Trade)?  Are there any class action suits for us?  The only class action suits I&#039;ve seen are for those who sold BIVN in May.</description>
		<content:encoded><![CDATA[<p>Is there any recourse for those of us who signed the agreement selling our BIVN shares to Genzyme thinking that it was a done deal (as explained to me by E-Trade)?  Are there any class action suits for us?  The only class action suits I&#8217;ve seen are for those who sold BIVN in May.</p>
]]></content:encoded>
	</item>
</channel>
</rss>
